Most Referred Kidney Patients Never Reach Waitlists Due to Evaluation Barriers and Inequities

Data from transplant centers show that after referral, patients encounter sequential hurdles including insurance verification, comorbidity screening, and psychosocial assessments that filter out the majority. Referral alone does not guarantee progression; financial instability and lack of transportation prevent completion of required testing in over 60 percent of cases. These patterns align with prior observational studies tracking 100,000+ patients through the evaluation pipeline.

Racial disparities persist even after controlling for medical eligibility, echoing findings from large cohort analyses in JAMA Surgery and the American Journal of Transplantation. Centers with predominantly White patient populations list referred individuals at nearly double the rate of safety-net facilities serving minority communities. This gap reflects systemic underinvestment in patient navigation rather than differences in disease severity alone.

Policy responses have focused on referral volume metrics while ignoring completion rates, allowing centers to meet volume targets without addressing downstream inequities. New CMS proposals to tie reimbursement to waitlist addition rates could shift incentives, yet implementation details remain unclear. Without standardized navigation support and reduced financial barriers, thousands of eligible patients will continue to be lost annually.

Future studies must track patients from referral through listing with granular socioeconomic data to identify precise intervention points and measure whether equity-focused policies narrow existing gaps.